Belgian pharmaceutical group UCB (Euronext Brussels: UCB) has announced a 35% rise in core profits.
The company’s 2015 annual report revealed an earnings before interest, tax, depreciation and amortization (EBITDA) figure of 821 million euros ($907.9 million) which was higher than industry analysts had predicted. Dividends were up by 4% to 1.10 euros from 1.06 euros last time.
And bosses have forecast further expansion of revenue and profit this year after three newer drugs drove earnings by more than expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze